ArticleNPJ precision oncology2020
Article in NPJ precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).British journal of cancer · 2026Article
- Article
- Prognostic Implications of SMARCA4, ARID1A, and Other BAF Mutations in Non-Small Cell Lung Cancer.Cancer medicine · 2025Review
- Case Report: Advanced grade 2 meningioma withFrontiers in oncology · 2025Article
- PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer.Theranostics · 2025Article
- Article
- Construction and verification of a histone deacetylases-related prognostic signature model for colon cancer.Scientific reports · 2024Article
- Comprehensive Immunogenomic Profiling ofJCO precision oncology · 2024Article
- To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.Journal of cancer research and clinical oncology · 2023Review
- Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma.Journal of clinical medicine · 2023Review
- Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.Biomolecules · 2023Review
- Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.Frontiers in immunology · 2023Article
- Genomic landscape of clinically advancedFrontiers in oncology · 2023Article
- An ErbB Lineage Co-Regulon Harbors Potentially Co-Druggable Targets for Multimodal Precision Therapy in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2022Article
- Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy.International journal of molecular sciences · 2022Review
- The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma.Journal of the National Cancer Center · 2022Article
- Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation.The oncologist · 2022Article
- Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy.The Journal of clinical investigation · 2022Review
- PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polybromo-1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.